EMA Authorised: Nexpovio (selinexor) — Stemline Therapeutics B.V.

View source ↗

Summary

Nexpovio (selinexor) has been authorised by the EMA for therapeutic use, with multiple myeloma as a indicated disease area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Nexpovio (Selinexor)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Stemline Therapeutics B.V.. Decision date: 26/03/2026